1
|
Brito MDF, Torre C, Silva-Lima B. Scientific Advances in Diabetes: The Impact of the Innovative Medicines Initiative. Front Med (Lausanne) 2021; 8:688438. [PMID: 34295913 PMCID: PMC8290522 DOI: 10.3389/fmed.2021.688438] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Accepted: 06/02/2021] [Indexed: 12/16/2022] Open
Abstract
Diabetes Mellitus is one of the World Health Organization's priority diseases under research by the first and second programmes of Innovative Medicines Initiative, with the acronyms IMI1 and IMI2, respectively. Up to October of 2019, 13 projects were funded by IMI for Diabetes & Metabolic disorders, namely SUMMIT, IMIDIA, DIRECT, StemBANCC, EMIF, EBiSC, INNODIA, RHAPSODY, BEAT-DKD, LITMUS, Hypo-RESOLVE, IM2PACT, and CARDIATEAM. In general, a total of €447 249 438 was spent by IMI in the area of Diabetes. In order to prompt a better integration of achievements between the different projects, we perform a literature review and used three data sources, namely the official project's websites, the contact with the project's coordinators and co-coordinator, and the CORDIS database. From the 662 citations identified, 185 were included. The data collected were integrated into the objectives proposed for the four IMI2 program research axes: (1) target and biomarker identification, (2) innovative clinical trials paradigms, (3) innovative medicines, and (4) patient-tailored adherence programmes. The IMI funded projects identified new biomarkers, medical and research tools, determinants of inter-individual variability, relevant pathways, clinical trial designs, clinical endpoints, therapeutic targets and concepts, pharmacologic agents, large-scale production strategies, and patient-centered predictive models for diabetes and its complications. Taking into account the scientific data produced, we provided a joint vision with strategies for integrating personalized medicine into healthcare practice. The major limitations of this article were the large gap of data in the libraries on the official project websites and even the Cordis database was not complete and up to date.
Collapse
Affiliation(s)
| | - Carla Torre
- Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.,Laboratory of Systems Integration Pharmacology, Clinical & Regulatory Science-Research Institute for Medicines (iMED.ULisboa), Lisbon, Portugal
| | - Beatriz Silva-Lima
- Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.,Laboratory of Systems Integration Pharmacology, Clinical & Regulatory Science-Research Institute for Medicines (iMED.ULisboa), Lisbon, Portugal
| |
Collapse
|
2
|
Jansen K, Evangelopoulou M, Pou Casellas C, Abrishamcar S, Jansen J, Vermonden T, Masereeuw R. Spinach and Chive for Kidney Tubule Engineering: the Limitations of Decellularized Plant Scaffolds and Vasculature. AAPS JOURNAL 2020; 23:11. [PMID: 33369701 PMCID: PMC7769781 DOI: 10.1208/s12248-020-00550-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/29/2020] [Accepted: 12/08/2020] [Indexed: 02/08/2023]
Abstract
Tissue decellularization yields complex scaffolds with retained composition and structure, and plants offer an inexhaustible natural source of numerous shapes. Plant tissue could be a solution for regenerative organ replacement strategies and advanced in vitro modeling, as biofunctionalization of decellularized tissue allows adhesion of various kinds of human cells that can grow into functional tissue. Here, we investigated the potential of spinach leaf vasculature and chive stems for kidney tubule engineering to apply in tubular transport studies. We successfully decellularized both plant tissues and confirmed general scaffold suitability for topical recellularization with renal cells. However, due to anatomical restrictions, we believe that spinach and chive vasculature themselves cannot be recellularized by current methods. Moreover, gradual tissue disintegration and deficient diffusion capacity make decellularized plant scaffolds unsuitable for kidney tubule engineering, which relies on transepithelial solute exchange between two compartments. We conclude that plant-derived structures and biomaterials need to be carefully considered and possibly integrated with other tissue engineering technologies for enhanced capabilities.
Collapse
Affiliation(s)
- Katja Jansen
- Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
| | - Marianna Evangelopoulou
- Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
| | - Carla Pou Casellas
- Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
| | - Sarina Abrishamcar
- Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
| | - Jitske Jansen
- Department of Pathology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands.,Department of Pediatric Nephrology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Amalia Children's Hospital, Nijmegen, The Netherlands
| | - Tina Vermonden
- Division of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
| | - Rosalinde Masereeuw
- Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. .,Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Universiteitsweg 99, 3584 CG, Utrecht, The Netherlands.
| |
Collapse
|
3
|
Sallam M, Palakkan AA, Mills CG, Tarnick J, Elhendawi M, Marson L, Davies JA. Differentiation of a Contractile, Ureter-Like Tissue, from Embryonic Stem Cell-Derived Ureteric Bud and Ex Fetu Mesenchyme. J Am Soc Nephrol 2020; 31:2253-2262. [PMID: 32826325 DOI: 10.1681/asn.2019101075] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2019] [Accepted: 06/11/2020] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND There is intense interest in replacing kidneys from stem cells. It is now possible to produce, from embryonic or induced pluripotent stem cells, kidney organoids that represent immature kidneys and display some physiologic functions. However, current techniques have not yet resulted in renal tissue with a ureter, which would be needed for engineered kidneys to be clinically useful. METHODS We used a published sequence of growth factors and drugs to induce mouse embryonic stem cells to differentiate into ureteric bud tissue. We characterized isolated engineered ureteric buds differentiated from embryonic stem cells in three-dimensional culture and grafted them into ex fetu mouse kidney rudiments. RESULTS Engineered ureteric buds branched in three-dimensional culture and expressed Hoxb7, a transcription factor that is part of a developmental regulatory system and a ureteric bud marker. When grafted into the cortex of ex fetu kidney rudiments, engineered ureteric buds branched and induced nephron formation; when grafted into peri-Wolffian mesenchyme, still attached to a kidney rudiment or in isolation, they did not branch but instead differentiated into multilayer ureter-like epithelia displaying robust expression of the urothelial marker uroplakin. This engineered ureteric bud tissue also organized the mesenchyme into smooth muscle that spontaneously contracted, with a period a little slower than that of natural ureteric peristalsis. CONCLUSIONS Mouse embryonic stem cells can be differentiated into ureteric bud cells. Grafting those UB-like structures into peri-Wolffian mesenchyme of cultured kidney rudiments can induce production of urothelium and organize the mesenchyme to produce rhythmically contracting smooth muscle layers. This development may represent a significant step toward the goal of renal regeneration.
Collapse
Affiliation(s)
- May Sallam
- Deanery of Biomedical Science, University of Edinburgh, Edinburgh, UK .,Human Anatomy and Embryology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
| | - Anwar A Palakkan
- Deanery of Biomedical Science, University of Edinburgh, Edinburgh, UK
| | | | - Julia Tarnick
- Deanery of Biomedical Science, University of Edinburgh, Edinburgh, UK
| | - Mona Elhendawi
- Deanery of Biomedical Science, University of Edinburgh, Edinburgh, UK.,Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
| | - Lorna Marson
- Edinburgh Transplant Centre, Royal Infirmary of Edinburgh, Edinburgh, UK
| | - Jamie A Davies
- Deanery of Biomedical Science, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
4
|
Davies JA, Glykofrydis F. Engineering pattern formation and morphogenesis. Biochem Soc Trans 2020; 48:1177-1185. [PMID: 32510150 PMCID: PMC7329343 DOI: 10.1042/bst20200013] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2020] [Revised: 05/14/2020] [Accepted: 05/18/2020] [Indexed: 12/14/2022]
Abstract
The development of natural tissues, organs and bodies depends on mechanisms of patterning and of morphogenesis, typically (but not invariably) in that order, and often several times at different final scales. Using synthetic biology to engineer patterning and morphogenesis will both enhance our basic understanding of how development works, and provide important technologies for advanced tissue engineering. Focusing on mammalian systems built to date, this review describes patterning systems, both contact-mediated and reaction-diffusion, and morphogenetic effectors. It also describes early attempts to connect the two to create self-organizing physical form. The review goes on to consider how these self-organized systems might be modified to increase the complexity and scale of the order they produce, and outlines some possible directions for future research and development.
Collapse
Affiliation(s)
- Jamie A. Davies
- Deanery of Biomedical Sciences and Centre for Mammalian Synthetic Biology, University of Edinburgh, U.K
| | - Fokion Glykofrydis
- Deanery of Biomedical Sciences and Centre for Mammalian Synthetic Biology, University of Edinburgh, U.K
| |
Collapse
|
5
|
Held M, Santeramo I, Wilm B, Murray P, Lévy R. Ex vivo live cell tracking in kidney organoids using light sheet fluorescence microscopy. PLoS One 2018; 13:e0199918. [PMID: 30048451 PMCID: PMC6062017 DOI: 10.1371/journal.pone.0199918] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Accepted: 06/16/2018] [Indexed: 12/28/2022] Open
Abstract
Screening cells for their differentiation potential requires a combination of tissue culture models and imaging methods that allow for long-term tracking of the location and function of cells. Embryonic kidney re-aggregation in vitro assays have been established which allow for the monitoring of organotypic cell behaviour in re-aggregated and chimeric renal organoids. However, evaluation of cell integration is hampered by the high photonic load of standard fluorescence microscopy which poses challenges for imaging three-dimensional systems in real-time over a time course. Therefore, we employed light sheet microscopy, a technique that vastly reduces photobleaching and phototoxic effects. We have also developed a new method for culturing the re-aggregates which involves immersed culture, generating organoids which more closely reflect development in vivo. To facilitate imaging from various angles, we embedded the organoids in a freely rotatable hydrogel cylinder. Endpoint fixing and staining were performed to provide additional biomolecular information. We succeeded in imaging labelled cells within re-aggregated kidney organoids over 15 hours and tracking their fate while simultaneously monitoring the development of organotypic morphological structures. Our results show that Wt1-expressing embryonic kidney cells obtained from transgenic mice could integrate into re-aggregated chimeric kidney organoids and contribute to developing nephrons. Furthermore, the nascent proximal tubules that formed in the re-aggregated tissues using the new culture method displayed secretory function, as evidenced by their ability to secrete an organic anion mimic into the tubular lumen.
Collapse
Affiliation(s)
- Marie Held
- Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom
| | - Ilaria Santeramo
- Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom
| | - Bettina Wilm
- Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom
| | - Patricia Murray
- Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom
| | - Raphaël Lévy
- Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom
| |
Collapse
|
6
|
An optimal serum-free defined condition for in vitro culture of kidney organoids. Biochem Biophys Res Commun 2018; 501:996-1002. [DOI: 10.1016/j.bbrc.2018.05.098] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2018] [Accepted: 05/15/2018] [Indexed: 12/21/2022]
|
7
|
Burton TP, Callanan A. A Non-woven Path: Electrospun Poly(lactic acid) Scaffolds for Kidney Tissue Engineering. Tissue Eng Regen Med 2018; 15:301-310. [PMID: 30603555 PMCID: PMC6171675 DOI: 10.1007/s13770-017-0107-5] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Revised: 11/15/2017] [Accepted: 12/03/2017] [Indexed: 01/26/2023] Open
Abstract
Chronic kidney disease is a major global health problem affecting millions of people; kidney tissue engineering provides an opportunity to better understand this disease, and has the capacity to provide a cure. Two-dimensional cell culture and decellularised tissue have been the main focus of this research thus far, but despite promising results these methods are not without their shortcomings. Polymer fabrication techniques such as electrospinning have the potential to provide a non-woven path for kidney tissue engineering. In this experiment we isolated rat primary kidney cells which were seeded on electrospun poly(lactic acid) scaffolds. Our results showed that the scaffolds were capable of sustaining a multi-population of kidney cells, determined by the presence of: aquaporin-1 (proximal tubules), aquaporin-2 (collecting ducts), synaptopodin (glomerular epithelia) and von Willebrand factor (glomerular endothelia cells), viability of cells appeared to be unaffected by fibre diameter. The ability of electrospun polymer scaffold to act as a conveyor for kidney cells makes them an ideal candidate within kidney tissue engineering; the non-woven path provides benefits over decellularised tissue by offering a high morphological control as well as providing superior mechanical properties with degradation over a tuneable time frame.
Collapse
Affiliation(s)
- Todd P. Burton
- Institute of Bioengineering, School of Engineering, The University of Edinburgh, Faraday Building, The King’s Buildings, Mayfield Road, Edinburgh, EH9 3JL UK
| | - Anthony Callanan
- Institute of Bioengineering, School of Engineering, The University of Edinburgh, Faraday Building, The King’s Buildings, Mayfield Road, Edinburgh, EH9 3JL UK
| |
Collapse
|
8
|
Kottamasu P, Herman I. Engineering a microcirculation for perfusion control of ex vivo-assembled organ systems: Challenges and opportunities. J Tissue Eng 2018; 9:2041731418772949. [PMID: 29780570 PMCID: PMC5952288 DOI: 10.1177/2041731418772949] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2018] [Accepted: 04/04/2018] [Indexed: 01/03/2023] Open
Abstract
Donor organ shortage remains a clear problem for many end-stage organ patients around the world. The number of available donor organs pales in comparison with the number of patients in need of these organs. The field of tissue engineering proposes a plausible solution. Using stem cells, a patient's autologous cells, or allografted cells to seed-engineered scaffolds, tissue-engineered constructs can effectively supplement the donor pool and bypass other problems that arise when using donor organs, such as who receives the organ first and whether donor organ rejection may occur. However, current research methods and technologies have been unable to successfully engineer and vascularize large volume tissue constructs. This review examines the current perfusion methods for ex vivo organ systems, defines the different types of vascularization in organs, explores various strategies to vascularize ex vivo organ systems, and discusses challenges and opportunities for the field of tissue engineering.
Collapse
Affiliation(s)
| | - Ira Herman
- Tufts University School of Medicine, Boston, MA, USA
| |
Collapse
|
9
|
Burton TP, Corcoran A, Callanan A. The effect of electrospun polycaprolactone scaffold morphology on human kidney epithelial cells. Biomed Mater 2017; 13:015006. [PMID: 29165317 DOI: 10.1088/1748-605x/aa8dde] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
There is a pressing need for further advancement in tissue engineering of functional organs with a view to providing a more clinically relevant model for drug development and reduce the dependence on organ donation. Polymer-based scaffolds, such as polycaprolactone (PCL), have been highlighted as a potential avenue for tissue engineered kidneys, but there is little investigation down this stream. Focus within kidney tissue engineering has been on two-dimensional cell culture and decellularised tissue. Electrospun polymer scaffolds can be created with a variety of fibre diameters and have shown a great potential in many areas. The variation in morphology of tissue engineering scaffold has been shown to effect the way cells behave and integrate. In this study we examined the cellular response to scaffold architecture of novel electrospun scaffold for kidney tissue engineering. Fibre diameters of 1.10 ± 0.16 μm and 4.49 ± 0.47 μm were used with three distinct scaffold architectures. Traditional random fibres were spun onto a mandrel rotating at 250 rpm, aligned at 1800 rpm with novel cryogenic fibres spun onto a mandrel loaded with dry ice rotating at 250 rpm. Human kidney epithelial cells were grown for 1 and 2 weeks. Fibre morphology had no effect of cell viability in scaffolds with a large fibre diameter but significant differences were seen in smaller fibres. Fibre diameter had a significant effect in aligned and cryogenic scaffold. Imaging detailed the differences in cell attachment due to scaffold differences. These results show that architecture of the scaffold has a profound effect on kidney cells; whether that is effects of fibre diameter on the cell attachment and viability or the effect of fibre arrangement on the distribution of cells and their alignment with fibres. Results demonstrate that PCL scaffolds have the capability to maintain kidney cells life and should be investigated further as a potential scaffold in kidney tissue engineering.
Collapse
Affiliation(s)
- Todd P Burton
- Institute for Bioengineering, School of Engineering, University of Edinburgh, Faraday Building, King's Buildings, EH9 3JL, United Kingdom
| | | | | |
Collapse
|
10
|
Abstract
Classical tissue engineering is aimed mainly at producing anatomically and physiologically realistic replacements for normal human tissues. It is done either by encouraging cellular colonization of manufactured matrices or cellular recolonization of decellularized natural extracellular matrices from donor organs, or by allowing cells to self-organize into organs as they do during fetal life. For repair of normal bodies, this will be adequate but there are reasons for making unusual, non-evolved tissues (repair of unusual bodies, interface to electromechanical prostheses, incorporating living cells into life-support machines). Synthetic biology is aimed mainly at engineering cells so that they can perform custom functions: applying synthetic biological approaches to tissue engineering may be one way of engineering custom structures. In this article, we outline the ‘embryological cycle’ of patterning, differentiation and morphogenesis and review progress that has been made in constructing synthetic biological systems to reproduce these processes in new ways. The state-of-the-art remains a long way from making truly synthetic tissues, but there are now at least foundations for future work.
Collapse
|
11
|
Jansen K, Schuurmans CCL, Jansen J, Masereeuw R, Vermonden T. Hydrogel-Based Cell Therapies for Kidney Regeneration: Current Trends in Biofabrication and In Vivo Repair. Curr Pharm Des 2017; 23:3845-3857. [PMID: 28699526 PMCID: PMC6302346 DOI: 10.2174/1381612823666170710155726] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2017] [Revised: 06/05/2017] [Accepted: 06/19/2017] [Indexed: 01/14/2023]
Abstract
Facing the problems of limited renal regeneration capacity and the persistent shortage of donor kidneys, dialysis remains the only treatment option for many end-stage renal disease patients. Unfortunately, dialysis is only a medium-term solution because large and protein-bound uremic solutes are not efficiently cleared from the body and lead to disease progression over time. Current strategies for improved renal replacement therapies (RRTs) range from whole organ engineering to biofabrication of renal assist devices and biological injectables for in vivo regeneration. Notably, all approaches coincide with the incorporation of cellular components and biomimetic micro-environments. Concerning the latter, hydrogels form promising materials as scaffolds and cell carrier systems due to the demonstrated biocompatibility of most natural hydrogels, tunable biochemical and mechanical properties, and various application possibilities. In this review, the potential of hydrogel-based cell therapies for kidney regeneration is discussed. First, we provide an overview of current trends in the development of RRTs and in vivo regeneration options, before examining the possible roles of hydrogels within these fields. We discuss major application-specific hydrogel design criteria and, subsequently, assess the potential of emergent biofabrication technologies, such as micromolding, microfluidics and electrodeposition for the development of new RRTs and injectable stem cell therapies.
Collapse
Affiliation(s)
- Katja Jansen
- Utrecht University Div. Pharmacology Department of Pharmaceutical Sciences Universiteitsweg 99, 3584 CG Utrecht. Netherlands
| | - Carl C L Schuurmans
- Utrecht University Div. Pharmacology Department of Pharmaceutical Sciences Universiteitsweg 99, 3584 CG Utrecht. Netherlands
| | - Jitske Jansen
- Utrecht University Div. Pharmacology Department of Pharmaceutical Sciences Universiteitsweg 99, 3584 CG Utrecht. Netherlands
| | - Rosalinde Masereeuw
- Utrecht University Div. Pharmacology Department of Pharmaceutical Sciences Universiteitsweg 99, 3584 CG Utrecht. Netherlands
| | - Tina Vermonden
- Utrecht University Div. Pharmacology Department of Pharmaceutical Sciences Universiteitsweg 99, 3584 CG Utrecht. Netherlands
| |
Collapse
|
12
|
Weber RJ, Cerchiari AE, Delannoy LS, Garbe JC, LaBarge MA, Desai TA, Gartner ZJ. Rapid Organoid Reconstitution by Chemical Micromolding. ACS Biomater Sci Eng 2016; 2:1851-1855. [DOI: 10.1021/acsbiomaterials.6b00421] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Affiliation(s)
- Robert J. Weber
- Department
of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States,
- Chemistry
and Chemical Biology Graduate Program, University of California, San Francisco, 600 16th Street, Room 522, San Francisco, California 94158, United States,
- Medical
Scientist Training Program, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, California 94143, United States
| | - Alec E. Cerchiari
- Department
of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States,
- UC Berkeley−UCSF Group in Bioengineering, 1700 Fourth Street, Room 216, San Francisco, California 94158, United States,
- UCSF Bioengineering and Therapeutic Sciences, 1700 Fourth Street, Room 216B, San Francisco, California 94158, United States
| | - Lucas S. Delannoy
- Laboratory
of Stem Cell Bioengineering, Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Station
15, Building Al 1106, CH-1015 Lausanne, Switzerland
| | - James C. Garbe
- Department
of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States,
- Life
Sciences Division, Lawrence Berkeley National Laboratory, 1 Cyclotron
Road, Berkeley, California 94720, United States
| | - Mark A. LaBarge
- Life
Sciences Division, Lawrence Berkeley National Laboratory, 1 Cyclotron
Road, Berkeley, California 94720, United States
| | - Tejal A. Desai
- UC Berkeley−UCSF Group in Bioengineering, 1700 Fourth Street, Room 216, San Francisco, California 94158, United States,
- UCSF Bioengineering and Therapeutic Sciences, 1700 Fourth Street, Room 216B, San Francisco, California 94158, United States
| | - Zev J. Gartner
- Department
of Pharmaceutical Chemistry, University of California, San Francisco, 600 16th Street, San Francisco, California 94158, United States,
- Chemistry
and Chemical Biology Graduate Program, University of California, San Francisco, 600 16th Street, Room 522, San Francisco, California 94158, United States,
- UC Berkeley−UCSF Group in Bioengineering, 1700 Fourth Street, Room 216, San Francisco, California 94158, United States,
| |
Collapse
|
13
|
Walker RSK, Cai Y. The Fifth Annual Sc2.0 and Synthetic Genomes Conference: Synthetic Genomes in High Gear. ACS Synth Biol 2016; 5:920-2. [PMID: 27633830 DOI: 10.1021/acssynbio.6b00227] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The Sc2.0 project is perhaps the largest synthetic biology project in the public domain, and ultimately aims to construct a new version of the humble brewer's yeast, Saccharomyces cerevisiae. Each year, the Sc2.0 consortium gather to discuss progress in this ambitious project and highlight new developments at the forefront of synthetic genome engineering. This viewpoint summarizes some of the key moments of the 2016 conference, including updates on the Sc2.0 project itself, mammalian synthetic biology, DNA assembly automation, HGP-Write and a panel discussion on the social and ethical perspectives of synthetic biology.
Collapse
Affiliation(s)
- Roy S. K. Walker
- Daniel
Rutherford Building G.24, School of Biological Sciences, University of Edinburgh, The King’s Buildings, Edinburgh EH9 3BF, United Kingdom
- Institute
for Bioengineering, School of Engineering, The University of Edinburgh, Edinburgh EH9 3BF, United Kingdom
| | - Yizhi Cai
- Daniel
Rutherford Building G.24, School of Biological Sciences, University of Edinburgh, The King’s Buildings, Edinburgh EH9 3BF, United Kingdom
| |
Collapse
|
14
|
Tanigawa S, Perantoni AO. Modeling renal progenitors - defining the niche. Differentiation 2016; 91:152-8. [PMID: 26856661 DOI: 10.1016/j.diff.2016.01.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Accepted: 01/27/2016] [Indexed: 11/15/2022]
Abstract
Significant recent advances in methodologies for the differentiation of pluripotent stem cells to renal progenitors as well as the definition of niche conditions for sustaining those progenitors have dramatically enhanced our understanding of their biology and developmental programing, prerequisites for establishing viable approaches to renal regeneration. In this article, we review the evolution of culture techniques and models for the study of metanephric development, describe the signaling mechanisms likely to be driving progenitor self-renewal, and discuss current efforts to generate de novo functional tissues, providing in depth protocols and niche conditions for the stabilization of the nephronic Six2+progenitor.
Collapse
Affiliation(s)
- Shunsuke Tanigawa
- Department of Kidney Development, Institute of Molecular Embryology and Genetics, Kumamoto University, 2-2-1 Honjo, Kumamoto 860-0811, Japan
| | - Alan O Perantoni
- Cancer and Developmental Biology Laboratory, National Cancer Institute-Frederick, Frederick, MD 21702, United States.
| |
Collapse
|
15
|
Kumar N, Richter J, Cutts J, Bush KT, Trujillo C, Nigam SK, Gaasterland T, Brafman D, Willert K. Generation of an expandable intermediate mesoderm restricted progenitor cell line from human pluripotent stem cells. eLife 2015; 4. [PMID: 26554899 PMCID: PMC4631902 DOI: 10.7554/elife.08413] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2015] [Accepted: 10/15/2015] [Indexed: 12/19/2022] Open
Abstract
The field of tissue engineering entered a new era with the development of human pluripotent stem cells (hPSCs), which are capable of unlimited expansion whilst retaining the potential to differentiate into all mature cell populations. However, these cells harbor significant risks, including tumor formation upon transplantation. One way to mitigate this risk is to develop expandable progenitor cell populations with restricted differentiation potential. Here, we used a cellular microarray technology to identify a defined and optimized culture condition that supports the derivation and propagation of a cell population with mesodermal properties. This cell population, referred to as intermediate mesodermal progenitor (IMP) cells, is capable of unlimited expansion, lacks tumor formation potential, and, upon appropriate stimulation, readily acquires properties of a sub-population of kidney cells. Interestingly, IMP cells fail to differentiate into other mesodermally-derived tissues, including blood and heart, suggesting that these cells are restricted to an intermediate mesodermal fate. DOI:http://dx.doi.org/10.7554/eLife.08413.001 The development of ‘human pluripotent stem cells’ has the potential to revolutionize the future of medicine. This is because these cells can both replicate themselves indefinitely (i.e., they can self-renew) and develop into any of the cell types found in the human body (a process that is referred to as differentiation). These abilities mean that the cells could in theory be used to replace any tissues or organs that have been damaged by disease or injury. Unfortunately, transplanting stem cells that are capable of developing into any type of cell comes with the significant risk that these cells will form into a tumor. Once a cell has started to differentiate it can typically only go on to generate a restricted number of cell types. However, these differentiating cells also generally lose their ability to self-renew. Kumar et al. set out to challenge this fundamental property of differentiating cells. A high throughput-screening approach was used to test thousands of combinations of bioactive molecules (i.e., molecules that are known to affect living cells in different ways) to identify some that could promote the self-renewal of cells with a restricted potential to differentiate. Kumar et al. found specific conditions that could cause a population of cells, which they referred to as ‘intermediate mesodermal progenitor cells’ (or IMP cells for short), to self renew. These cells resemble those found in the middle layer of a very early human embryo, which typically go on to develop into only a subset of tissue types in the body—for example, muscle, kidneys and blood vessels, but not brain or lungs. Yet, when Kumar et al. stimulated the self-renewing IMP cells, these cells only differentiated into the cell types that make up the kidney and not any other types of cell. This tight restriction on the differentiation potential of these cells is highly important, because it means that these cells could greatly advance methods to generate kidney cells or even whole kidneys in the laboratory that are suitable for transplantation. DOI:http://dx.doi.org/10.7554/eLife.08413.002
Collapse
Affiliation(s)
- Nathan Kumar
- Department of Cellular and Molecular Medicine, University of California, San Diego, San Diego, United States
| | - Jenna Richter
- Department of Cellular and Molecular Medicine, University of California, San Diego, San Diego, United States
| | - Josh Cutts
- School of Biological and Health Systems Engineering, Arizona State University, Tempe, United States
| | - Kevin T Bush
- Department of Pediatrics, University of California, San Diego, San Diego, United States
| | - Cleber Trujillo
- Department of Pediatrics, University of California, San Diego, San Diego, United States
| | - Sanjay K Nigam
- Department of Cellular and Molecular Medicine, University of California, San Diego, San Diego, United States.,Department of Pediatrics, University of California, San Diego, San Diego, United States
| | - Terry Gaasterland
- Scripps Institution of Oceanography, Scripps Genome Center, University of California, San Diego, San Diego, United States
| | - David Brafman
- School of Biological and Health Systems Engineering, Arizona State University, Tempe, United States
| | - Karl Willert
- Department of Cellular and Molecular Medicine, University of California, San Diego, San Diego, United States
| |
Collapse
|
16
|
Davies JA. Synthetic Biology: Rational Pathway Design for Regenerative Medicine. Gerontology 2015; 62:564-70. [PMID: 26474207 DOI: 10.1159/000440721] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2015] [Accepted: 08/31/2015] [Indexed: 11/19/2022] Open
Abstract
Rational pathway design is the invention of an optimally efficient route from one state (e.g. chemical structure, state of differentiation, physiological state) to another, based on knowledge of biological processes: it contrasts with the use of natural pathways that have evolved by natural selection. Synthetic biology is a hybrid discipline of biology and engineering that offers a means for rationally designed pathways to be realized in living cells. Several areas of regenerative medicine could benefit from rational pathway design, including derivation of patient-specific stem cells, directed differentiation of stem cells, replicating physiological function in an alternative cell type, construction of custom interface tissues and building fail-safe systems into transplanted tissues. Synthetic biological approaches offer the potential for construction of these, for example controllable ex vivo stem cell niches, genetic networks for direct transdifferentiation from adult fibroblast to restricted stem cell without going via induced pluripotent stem cells, signalling pathways for realizing physiological regulation in alternative cell types, morphological modules for producing self-constructing novel 'tissues' and 'kill-switches' for therapeutically applied stem cells. Given the potential of this approach, a closer convergence of the regenerative medicine and synthetic biology research fields seems timely.
Collapse
Affiliation(s)
- Jamie A Davies
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
17
|
Davies JA. Self-organized Kidney Rudiments: Prospects for Better in vitro Nephrotoxicity Assays. Biomark Insights 2015; 10:117-23. [PMID: 26244008 PMCID: PMC4507472 DOI: 10.4137/bmi.s20056] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2015] [Revised: 03/08/2015] [Accepted: 03/11/2015] [Indexed: 12/29/2022] Open
Abstract
Kidneys are essential to life but vulnerable to a range of toxicants, including therapeutic drugs and their metabolites. Indeed, nephrotoxicity is often a limiting factor in both drug use and drug development. Most toxicants damage kidneys by one of four mechanisms: damage to the membrane and its junctions, oxidative stress and free radical generation, activation of inflammatory processes, and interference with vascular regulation. Traditionally, animal models were used in preclinical screening for nephrotoxicity, but these can be poorly predictive of human reactions. Animal screens have been joined by simple single-cell–type in vitro assays using primary or immortalized human cells, particularly proximal tubule cells as these are especially vulnerable to toxicants. Recent research, aimed mainly at engineering new kidneys for transplant purposes, has resulted in a method for constructing anatomically realistic mini-kidneys from renogenic stem cells. So far, this has been done only using renogenic stem cells obtained directly from mouse embryos but, in principle, it should be possible to make them from renogenically directed human-induced pluripotent cells. If this can be done, the resulting human-based mini-kidneys would be a promising system for detecting some types of nephrotoxicity and for developing nephroprotective drugs.
Collapse
Affiliation(s)
- Jamie A Davies
- Centre for Integrative Physiology, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
18
|
Yuri S, Nishikawa M, Yanagawa N, Jo OD, Yanagawa N. Maintenance of Mouse Nephron Progenitor Cells in Aggregates with Gamma-Secretase Inhibitor. PLoS One 2015; 10:e0129242. [PMID: 26075891 PMCID: PMC4468097 DOI: 10.1371/journal.pone.0129242] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Accepted: 05/06/2015] [Indexed: 01/27/2023] Open
Abstract
Knowledge on how to maintain and expand nephron progenitor cells (NPC) in vitro is important to provide a potentially valuable source for kidney replacement therapies. In our present study, we examined the possibility of optimizing NPC maintenance in the "re-aggregate" system. We found that Six2-expressing (Six2(+))-NPC could be maintained in aggregates reconstituted with dispersed cells from E12.5 mouse embryonic kidneys for at least up to 21 days in culture. The maintenance of Six2(+)-NPC required the presence of ureteric bud cells. The number of Six2(+)-NPC increased by more than 20-fold at day 21, but plateaued after day 14. In an attempt to further sustain NPC proliferation by passage subculture, we found that the new (P1) aggregates reconstituted from the original (P0) aggregates failed to maintain NPC. However, based on the similarity between P1 aggregates and aggregates derived from E15.5 embryonic kidneys, we suspected that the differentiated NPC in P1 aggregates may interfere with NPC maintenance. In support of this notion, we found that preventing NPC differentiation by DAPT, a γ-secretase inhibitor that inhibits Notch signaling pathway, was effective to maintain and expand Six2(+)-NPC in P1 aggregates by up to 65-fold. The Six2(+)-NPC in P1 aggregates retained their potential to epithelialize upon exposure to Wnt signal. In conclusion, we demonstrated in our present study that the "re-aggregation" system can be useful for in vitro maintenance of NPC when combined with γ-secretase inhibitor.
Collapse
Affiliation(s)
- Shunsuke Yuri
- Medical and Research Services, Greater Los Angeles Veterans Affairs Healthcare System at Sepulveda, North Hills, California, United States of America
- University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California, United States of America
- * E-mail: (SY); (NY)
| | - Masaki Nishikawa
- Medical and Research Services, Greater Los Angeles Veterans Affairs Healthcare System at Sepulveda, North Hills, California, United States of America
- University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California, United States of America
| | - Naomi Yanagawa
- Medical and Research Services, Greater Los Angeles Veterans Affairs Healthcare System at Sepulveda, North Hills, California, United States of America
- University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California, United States of America
| | - Oak D. Jo
- Medical and Research Services, Greater Los Angeles Veterans Affairs Healthcare System at Sepulveda, North Hills, California, United States of America
- University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California, United States of America
| | - Norimoto Yanagawa
- Medical and Research Services, Greater Los Angeles Veterans Affairs Healthcare System at Sepulveda, North Hills, California, United States of America
- University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, California, United States of America
- * E-mail: (SY); (NY)
| |
Collapse
|
19
|
Peloso A, Katari R, Murphy SV, Zambon JP, DeFrancesco A, Farney AC, Rogers J, Stratta RJ, Manzia TM, Orlando G. Prospect for kidney bioengineering: shortcomings of the status quo. Expert Opin Biol Ther 2015; 15:547-58. [PMID: 25640286 DOI: 10.1517/14712598.2015.993376] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Dialysis and renal transplantation are the only two therapeutic options offered to patients affected by end-stage kidney disease; however, neither treatment can be considered definitive. In fact, dialysis is able to replace only the filtration function of the kidney without substituting its endocrine and metabolic roles, and dramatically impacts on patient's quality of life. On the other hand, kidney transplantation is severely limited by the shortage of transplantable organs, the need for immunosuppressive therapies and a narrow half-life. Regenerative medicine approaches are promising tools aiming to improve this condition. AREAS COVERED Cell therapies, bioartificial kidney, organ bioengineering, 3D printer and kidney-on-chip represent the most appealing areas of research for the treatment of end-stage kidney failure. The scope of this review is to summarize the state of the art, limits and directions of each branch. EXPERT OPINION In the future, these emerging technologies could provide definitive, curative and theoretically infinite options for the treatment of end-stage kidney disease. Progress in stem cells-based therapies, decellularization techniques and the more recent scientific know-how for the use of the 3D printer and kidney-on-chip could lead to a perfect cellular-based therapy, the futuristic creation of a bioengineered kidney in the lab or to a valid bioartificial alternative.
Collapse
Affiliation(s)
- Andrea Peloso
- Wake Forest School of Medicine , Winston-Salem, NC , USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|